OFA Group (OFAL) Form 10-Q — Aug 14, 2026
OFA Group's fiscal first-quarter 10-Q shows a net loss of $1,901,151 on revenue of just $14,879 (down 21.5% year over year), leaving an accumulated deficit of $11,060,535 and a working capital deficit of $4,577,805. The filing states these conditions raised substantial doubt about the company's ability to continue as a going concern, though management says mitigation plans — including tokenization proceeds, PIPE access, and cost control — alleviate that doubt. Liquidity is thin: unrestricted cash was only $178,057 at June 30, 2026, with another $1,680,000 locked in escrow with affiliate Finuvia LLC.
Key figures
- Revenue
- 14879
- Revenue Yoy
- -21.5%
- Total Assets
- 19812057
- Cash Position
- 178057
- Shares Outstanding
- 3793676
- Restricted cash
- 1680000
- Gross margin pct
- 73.27%
- Nasdaq deficiency
- notice December 17, 2025; initial compliance deadline June 9, 2026 not met; compliance confirmation pending
- Reverse split ratio
- 1:10
- Vero60 platform fee
- 7500000
- Gross profit quarter
- 10902
- Pipe stated value max
- 50000000
- Atsion equity facility
- 100000000
- Commitment fee payable
- 897175
- Md queens platform fee
- 15000000
- Quarterly amortization
- 881609
- Shares outstanding note
- 3,793,676 Class A and 20,000,000 Class B (25 votes/share) as of August 13, 2026
- Qikbim ip purchase price
- 17500000
- Backlog remaining revenue
- 569840
- Missed atsion installment
- 350000
- Unpaid intangible balance
- 5501361
- Top customer concentration
- Yan Chai Hospital 47.66% of quarterly revenue
- Ppdf tokens carried at zero
- 12,500,000 (MD Queens) + 6,250,000 (Vero 60)
- Total cash and restricted cash
- 1858057
- Atsion default shares requested
- 300000
- Atsion shares issued aug13 2026
- 450000
- Intangibles net carrying amount
- 15178818
- Vero60 project stabilized value
- 500000000
Price after filing
Close on the filing date to close N calendar days later (from $1.09). Historical, not a forecast.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.